STRO Earnings & Financial Statements
Sutro Biopharma, Inc.
$10.52
-$0.49(-4.45%)
39
Overall
40
Value
36
Tech
42
Quality
Market Cap
$174.43M
Volume
489.52K
52W Range
$7.15 - $43.85
Target Price
$47.23
STRO earnings and financial statements: Sutro Biopharma, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
STRO Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $102.48M | $62.04M | $153.73M | $67.77M | $61.88M |
| Operating income | -$158.37M | -$238.45M | -$89.28M | -$128.94M | -$98.52M |
| EBITDA | -$183.88M | -$217.86M | -$81.79M | -$107.66M | -$97.56M |
| Net income | -$191.09M | -$227.46M | -$106.79M | -$119.20M | -$105.54M |
| EPS (diluted) | $-22.49 | $-29.60 | $-17.80 | $-23.50 | $-22.90 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $173.83M | $387.21M | $470.74M | $406.94M | $341.41M |
| Total liabilities | $306.28M | $342.61M | $321.09M | $189.90M | $88.84M |
| Shareholders’ equity | -$132.45M | $44.60M | $149.65M | $217.05M | $252.56M |
| Cash and equivalents | $58.13M | $190.30M | $69.27M | $47.25M | $30.41M |
| Long-term debt | $7.89M | $15.67M | $23.15M | $33.34M | $46.96M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$177.23M | -$191.54M | -$111.62M | $3.55M | -$81.68M |
| Capital expenditure | - | -$3.10M | -$4.32M | -$7.86M | -$15.32M |
| Free cash flow | -$177.23M | -$191.54M | -$115.93M | -$4.31M | -$97.00M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | STRO | $10.52 | -4.5% | 489.52K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |